Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.57 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | METAP2 | P50579 | 1/20 | 0.52 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.51 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.51 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL27543075 | 0.92 | ALDH1A1 (0.66) | ALDH1A1KDM4EHSD17B10POLBTDP1 | |
| SCHEMBL796957 | 0.87 | ALDH1A1 (0.73) | ALDH1A1KDM4EHSD17B10POLBTDP1 | |
| SCHEMBL3915465 | 0.86 | ALDH1A1 (0.61) | ALDH1A1KDM4EHSD17B10POLBAKR1C2 | |
| SCHEMBL26170005 | 0.84 | ALDH1A1 (0.69) | ALDH1A1KDM4EHSD17B10POLBTDP1 | |
| SCHEMBL29144725 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KDM4EHSD17B10POLBAKR1C2 | |
| SCHEMBL7532175 | 0.83 | POLB (0.68) | ALDH1A1KDM4EPOLBTDP1AKR1C2 | |
| SCHEMBL14339913 | 0.83 | POLB (0.56) | ALDH1A1KDM4EHSD17B10POLBTDP1 | |
| SCHEMBL5899451 | 0.83 | ALDH1A1 (0.67) | ALDH1A1KDM4EHSD17B10POLBHTT | |
| SCHEMBL11827919 | 0.82 | MAPT (0.76) | ALDH1A1POLBHTTMEN1KMT2A | |
| SCHEMBL7544693 | 0.82 | KDM4E (0.59) | ALDH1A1KDM4EPOLBTDP1AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-113912487-B | Synthesis method of 2, 5-dihalobenzoic acid | 山东研峰新材料科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-113912487-A | Synthesis method of 2, 5-bis-halogenated benzoic acid | 山东研峰新材料科技有限公司 | 2022-01-11 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| CN-118420455-A | Preparation method of 2-chloro-5-bromobenzoic acid | 枣庄市润安制药新材料有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-113912487-B | Synthesis method of 2, 5-dihalobenzoic acid | 山东研峰新材料科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-113912487-A | Synthesis method of 2, 5-bis-halogenated benzoic acid | 山东研峰新材料科技有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-12-04 | — | — | US | disclosed |
| US-8624056-B2 | Halogenated analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD | 2014-01-07 | — | — | US | disclosed |
| US-8299023-B2 | Neuropeptide-2 receptor (Y-2R) agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20030008893-A1 | Modulators of chemokine receptor activity | COLON-CRUZ ROBERTO (US) | 2003-01-09 | — | — | US | disclosed |
| US-6479548-B2 | P-(BENZOYLAMINO)STILBENE DERIVATIVES | TELIK, INC. | 2002-11-12 | — | — | US | disclosed |
| WO-2002070523-A1 | MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | PFIZER PRODUCTS INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020032218-A1 | Substituted stilbenes as glucose uptake enhancers | TELIK, INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2001094295-A1 | SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS | TELIK, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-4307113-A | TREATMENT OF DIABETES | SANDOZ, INC. (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | NFATC1, AADAC, NAT1 | ALDH1A1 201/4885KDM4E 1605/4885HSD17B10 2237/4885 |
| US-20030008893-A1 | Modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | ALDH1A1 1764/4885KDM4E 4790/4885HSD17B10 2587/4885 |
| US-20020032218-A1 | Substituted stilbenes as glucose uptake enhancers | SLC2A1, SLC2A8, SLC2A2 | ALDH1A1 1811/4885KDM4E 3079/4885HSD17B10 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.